miR-501-3p在腎癌中的抑癌作用及其機(jī)制研究
發(fā)布時(shí)間:2021-12-09 17:39
背景:腎癌即腎細(xì)胞癌(renal cell carcinoma),是泌尿系統(tǒng)常見(jiàn)的惡性腫瘤之一,其起源于腎實(shí)質(zhì)泌尿小管上皮系統(tǒng),占腎臟惡性腫瘤的80%~90%,發(fā)病率約占全身腫瘤的2.1%。近年來(lái)由于吸煙、飲食變化等原因,腎癌發(fā)病率有逐漸上升的趨勢(shì)。腎癌易進(jìn)展,預(yù)后差,且其分子機(jī)制尚不明確。闡明腎癌發(fā)生發(fā)展的生物學(xué)機(jī)制,對(duì)于腎癌早期診斷及治療具有重要的臨床意義。microRNAs(miRNAs)是一類(lèi)由內(nèi)源性基因編碼的非編碼RNA,通過(guò)靶向基因mRNA3’端非編碼區(qū)調(diào)控基因表達(dá)。研究表明miRNAs如miR-501-3p參與腫瘤的發(fā)生發(fā)展,過(guò)表達(dá)miR-501-3p可抑制前列腺癌細(xì)胞增殖和集落形成,并誘導(dǎo)細(xì)胞周期G1期阻滯。miR-501-3p在肺癌、大腸癌、胰腺導(dǎo)管腺癌等腫瘤中也有促癌或抑癌作用。但miR-501-3p在腎癌中的表達(dá)模式及其生物學(xué)功能仍缺乏系統(tǒng)性研究,其對(duì)腎癌細(xì)胞增殖、遷移的影響及其分子機(jī)制尚不明確。目的:通過(guò)生物信息學(xué)網(wǎng)站分析miR-501-3p在腎癌中的表達(dá)模式并分析其表達(dá)下調(diào)的表觀遺傳學(xué)機(jī)制。采用一系列功能實(shí)驗(yàn)探究miR-501-3p在腎癌中的生物學(xué)功能。利用生...
【文章來(lái)源】:浙江大學(xué)浙江省 211工程院校 985工程院校 教育部直屬院校
【文章頁(yè)數(shù)】:120 頁(yè)
【學(xué)位級(jí)別】:博士
【部分圖文】:
圖2.4.1?TCGA數(shù)據(jù)庫(kù)分析517例腎癌組織與71例正常腎臟組織中miR-501-3p表??達(dá)量圖譜
3p?in?KIRC?Cancer??V%.?Log-Rank?p=054?—hjgh??Low?Num=259??High?Num=258?low??Hazard?Ratio=0.91?+?(high.i)??0-75'?+?(low,”??i??I??^0.50-?.?H.師?l??????S?it?"?irimni?i?11?n?h??i?1???(US.??0.00-??0?50?100?150??Time(months)??圖2.4.2?TCGA數(shù)據(jù)庫(kù)分析腎癌患者總體生存率與miR-501-3p表達(dá)量的關(guān)系6??miR-501-3p低表達(dá)患者與miR-501-3p高表達(dá)患者的總體生存率無(wú)顯著差異??(p=0.54)p??Putativ*?TSS*??Rank?Position?(To?pracursor)?Scot*?Con—>v?Mon?Mock?Eat?start?Upttraam??[1?廠?49769141?(51<9)?0.514269???0?GrtM??Eip*rim*ntal?Hatur—??〇?500?bp?1000?bp?1500?bp?2000?bp?2900?bp?3000?bp?3500?bp?4000?bp?4500?U??CpC?I??Fl?—IR1??F2l ̄|R2??F3l ̄|R3??Ml ̄|R4??F5l—|R9??Input?Sequence?Bisulfite?PCR?prlwr?NSP?Priner?S?t?CpC?Island??■?_?Iteth^latcd-Spectflc?■?■
3p?in?KIRC?Cancer??V%.?Log-Rank?p=054?—hjgh??Low?Num=259??High?Num=258?low??Hazard?Ratio=0.91?+?(high.i)??0-75'?+?(low,”??i??I??^0.50-?.?H.師?l??????S?it?"?irimni?i?11?n?h??i?1???(US.??0.00-??0?50?100?150??Time(months)??圖2.4.2?TCGA數(shù)據(jù)庫(kù)分析腎癌患者總體生存率與miR-501-3p表達(dá)量的關(guān)系6??miR-501-3p低表達(dá)患者與miR-501-3p高表達(dá)患者的總體生存率無(wú)顯著差異??(p=0.54)p??Putativ*?TSS*??Rank?Position?(To?pracursor)?Scot*?Con—>v?Mon?Mock?Eat?start?Upttraam??[1?廠?49769141?(51<9)?0.514269???0?GrtM??Eip*rim*ntal?Hatur—??〇?500?bp?1000?bp?1500?bp?2000?bp?2900?bp?3000?bp?3500?bp?4000?bp?4500?U??CpC?I??Fl?—IR1??F2l ̄|R2??F3l ̄|R3??Ml ̄|R4??F5l—|R9??Input?Sequence?Bisulfite?PCR?prlwr?NSP?Priner?S?t?CpC?Island??■?_?Iteth^latcd-Spectflc?■?■
【參考文獻(xiàn)】:
期刊論文
[1]Emerging role of microRNAs in cancer stem cells:Implications in cancer therapy[J]. Minal Garg. World Journal of Stem Cells. 2015(08)
[2]Noncoding RNAs in cancer and cancer stem cells[J]. Tianzhi Huang,Angel Alvarez,Bo Hu,Shi-Yuan Cheng. Chinese Journal of Cancer. 2013(11)
本文編號(hào):3531031
【文章來(lái)源】:浙江大學(xué)浙江省 211工程院校 985工程院校 教育部直屬院校
【文章頁(yè)數(shù)】:120 頁(yè)
【學(xué)位級(jí)別】:博士
【部分圖文】:
圖2.4.1?TCGA數(shù)據(jù)庫(kù)分析517例腎癌組織與71例正常腎臟組織中miR-501-3p表??達(dá)量圖譜
3p?in?KIRC?Cancer??V%.?Log-Rank?p=054?—hjgh??Low?Num=259??High?Num=258?low??Hazard?Ratio=0.91?+?(high.i)??0-75'?+?(low,”??i??I??^0.50-?.?H.師?l??????S?it?"?irimni?i?11?n?h??i?1???(US.??0.00-??0?50?100?150??Time(months)??圖2.4.2?TCGA數(shù)據(jù)庫(kù)分析腎癌患者總體生存率與miR-501-3p表達(dá)量的關(guān)系6??miR-501-3p低表達(dá)患者與miR-501-3p高表達(dá)患者的總體生存率無(wú)顯著差異??(p=0.54)p??Putativ*?TSS*??Rank?Position?(To?pracursor)?Scot*?Con—>v?Mon?Mock?Eat?start?Upttraam??[1?廠?49769141?(51<9)?0.514269???0?GrtM??Eip*rim*ntal?Hatur—??〇?500?bp?1000?bp?1500?bp?2000?bp?2900?bp?3000?bp?3500?bp?4000?bp?4500?U??CpC?I??Fl?—IR1??F2l ̄|R2??F3l ̄|R3??Ml ̄|R4??F5l—|R9??Input?Sequence?Bisulfite?PCR?prlwr?NSP?Priner?S?t?CpC?Island??■?_?Iteth^latcd-Spectflc?■?■
3p?in?KIRC?Cancer??V%.?Log-Rank?p=054?—hjgh??Low?Num=259??High?Num=258?low??Hazard?Ratio=0.91?+?(high.i)??0-75'?+?(low,”??i??I??^0.50-?.?H.師?l??????S?it?"?irimni?i?11?n?h??i?1???(US.??0.00-??0?50?100?150??Time(months)??圖2.4.2?TCGA數(shù)據(jù)庫(kù)分析腎癌患者總體生存率與miR-501-3p表達(dá)量的關(guān)系6??miR-501-3p低表達(dá)患者與miR-501-3p高表達(dá)患者的總體生存率無(wú)顯著差異??(p=0.54)p??Putativ*?TSS*??Rank?Position?(To?pracursor)?Scot*?Con—>v?Mon?Mock?Eat?start?Upttraam??[1?廠?49769141?(51<9)?0.514269???0?GrtM??Eip*rim*ntal?Hatur—??〇?500?bp?1000?bp?1500?bp?2000?bp?2900?bp?3000?bp?3500?bp?4000?bp?4500?U??CpC?I??Fl?—IR1??F2l ̄|R2??F3l ̄|R3??Ml ̄|R4??F5l—|R9??Input?Sequence?Bisulfite?PCR?prlwr?NSP?Priner?S?t?CpC?Island??■?_?Iteth^latcd-Spectflc?■?■
【參考文獻(xiàn)】:
期刊論文
[1]Emerging role of microRNAs in cancer stem cells:Implications in cancer therapy[J]. Minal Garg. World Journal of Stem Cells. 2015(08)
[2]Noncoding RNAs in cancer and cancer stem cells[J]. Tianzhi Huang,Angel Alvarez,Bo Hu,Shi-Yuan Cheng. Chinese Journal of Cancer. 2013(11)
本文編號(hào):3531031
本文鏈接:http://sikaile.net/yixuelunwen/zlx/3531031.html
最近更新
教材專(zhuān)著